Tolerability and safety profile of posaconazole: Evaluation of 18 controlled studies in healthy volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 3, 2009, Pages 301-311

  Moton, A ^a   Krishna, G ^a   Wang, Z ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Drug safety; Healthy volunteers; Pharmacokinetics; Posaconazole; Safety; Tolerability

Indexed keywords

PLACEBO; POSACONAZOLE;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD PRESSURE; CERVICAL LYMPHADENOPATHY; CONTROLLED STUDY; DEMOGRAPHY; DIZZINESS; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ELECTROCARDIOGRAPHY; EYE PAIN; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; KIDNEY FUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; MULTIPLE DRUG DOSE; MYCOSIS; NORMAL HUMAN; PROPHYLAXIS; QT INTERVAL; QT PROLONGATION; RACE; SEX RATIO; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VITAL SIGN; VOLUNTEER; XEROSTOMIA;

ADOLESCENT; AGED; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CLINICAL TRIALS, PHASE I AS TOPIC; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; TRIAZOLES; XEROSTOMIA; YOUNG ADULT;

EID: 65549095093     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01055.x     Document Type: Article

References (30)

1. Herbrecht R (2004) Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. International Journal of Clinical Practice, 58, 612 624. (Pubitemid 38996992)
2. Roden DM (2004) Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350, 1013 1022. (Pubitemid 38269278)
3. Keating GM (2005) Posaconazole. Drugs, 11, 1553 1567. (Pubitemid 41124308)
4. Cornely OA, Maertens J, Winston DJ et al. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. New England Journal of Medicine, 356, 348 359. (Pubitemid 46148777)
5. Ullmann AJ, Lipton JH, Vesole DH et al. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. New England Journal of Medicine, 356, 335 347. (Pubitemid 46148776)
6. Raad I, Chapman S, Bradsher R, et al. (2004) Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). Poster presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2 Washington, DC.
7. Vazquez JA, Skiest DJ, Nieto L et al. (2006) A multicenter, randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clinical Infectious Diseases, 42, 1179 1186.
8. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP (2006) Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clinical Infectious Diseases, 42, e61 e65.
9. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP (2006) Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clinical Infectious Diseases, 42, 1398 1403.
10. Courtney R, Pai S, Laughlin M, Lim J, Batra V (2003) Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrobial Agents and Chemotherapy, 47, 2788 2795. (Pubitemid 37040249)
11. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M (2003) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. British Journal of Clinical Pharmacology, 57, 218 222.
12. Courtney R, Radwanski E, Lim J, Laughlin M (2004) Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrobial Agents and Chemotherapy, 48, 804 808. (Pubitemid 38280328)
13. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, Saltzman MA (2006) Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrobial Agents and Chemotherapy, 50, 1881 1883.
14. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M (2005) Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clinical Pharmacokinetics, 44, 211 220. (Pubitemid 40188942)
15. Krishna G, Sansone-Parsons A (2006) Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition, December 3-7 Anaheim, CA.
16. Sansone-Parsons A, Krishna G, Simon J, Soni P, Kantesaria B, Herron J, Stoltz R (2007) Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrobial Agents and Chemotherapy, 51, 495 502. (Pubitemid 46185266)
17. National Cancer Institute (1999) Cancer therapy evaluation program. common toxicity criteria manual. version 2.0. Bethesda, Md : National Cancer Institute.
18. Funck-Brentano C, Jaillon P (1993) Rate-corrected QT interval: techniques and limitations. American Journal of Cardiology, 72, 17B 22B. (Pubitemid 23249059)
19. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. (1995) Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clinical Infectious Diseases, 21, 594 598.
20. ® [prescribing information] (2002). Kalamazoo, Mich : Pharmacia & Upjohn Company, February.
21. Petraitiene R, Petraitis V, Groll AH et al. (2001) Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrobial Agents and Chemotherapy, 45, 857 869.
22. Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, Anaissie EJ (2006) Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrobial Agents and Chemotherapy, 50, 1993 1999. (Pubitemid 43807517)
23. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L (2007) Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrobial Agents and Chemotherapy, 51, 812 818. (Pubitemid 46355260)
24. Ullmann AJ, Cornely OA, Burchardt A et al. (2006) Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrobial Agents and Chemotherapy, 50, 658 666. (Pubitemid 43190980)
25. Raad II, Graybill JR, Bustamante AB et al. (2006) Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clinical Infectious Diseases, 42, 1726 1734. (Pubitemid 43839438)
26. Walsh TJ, Goodman JL, Pappas P et al. (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrobial Agents and Chemotherapy, 45, 3487 3496. (Pubitemid 33107867)
27. Ahmad SR, Singer SJ, Leissa BG (2001) Congestive heart failure associated with itraconazole. Lancet, 357, 1766 1767. (Pubitemid 32524211)
28. Vazquez JA, Skiest DJ, Nieto L et al. (2006) A multicenter, randomized trial evaluating posaconazole versus fluconazole for oropharyngeal candidiasis in subjects with HIV/AIDS. Clinical Infectious Diseases, 42, 1179 1186.
29. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD (2003) Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. British Journal of Clinical Pharmacology, 56, 10 16. (Pubitemid 37491728)
30. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D (2003) The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. British Journal of Clinical Pharmacology, 56, 2 9. (Pubitemid 37491727)